{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:54:13Z","timestamp":1784138053143,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Atopic dermatitis (AD) is a chronic heterogeneous condition characterized by erythematous, pruritic, and inflamed skin. Janus kinase (JAK) inhibitors are a new class of drugs that target proteins in the Janus kinase\u2010signal transducer and activator of transcription (JAK\u2010STAT) pathway. These drugs can be administered orally or topically to inhibit signaling of the JAK\u2010STAT pathway and minimize the production of proinflammatory cytokines. The efficacy and safety of JAK inhibitors have been investigated in phase 2 and 3 clinical trials for AD. The safety of new medications, which are immunosuppressive by nature, is of utmost concern for the prescriber and patient alike. Herein we summarize the safety results of clinical trials using oral abrocitinib, upadacitinib, and baricitinib, as well as topical ruxolitinib and delgocitinib for the treatment of AD. The most prevalent (2\u20135% occurrence rate) treatment\u2010emergent adverse events from oral JAK inhibitor use in AD were nausea, upper respiratory tract infection, headache, herpes zoster, herpes simplex, acne, increased blood creatine phosphokinase levels, and decreased platelet counts. Topical JAK inhibitors were not associated with systemic effects. All studies reported that JAK inhibitors were well tolerated in patients with AD in comparison with the control group. While the use of JAK inhibitors in patients suffering from AD is very promising, trials reported to date are of short duration (maximum 16\u2009weeks), and more information on the long\u2010term safety of these novel agents is required.<\/jats:p>","DOI":"10.1111\/ijd.15853","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T05:34:06Z","timestamp":1629696846000},"page":"746-754","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety of Janus kinase (JAK) inhibitors in the short\u2010term treatment of atopic dermatitis"],"prefix":"10.1111","volume":"61","author":[{"given":"Hannah","family":"Wood","sequence":"first","affiliation":[{"name":"Trent University  1600 West Bank Dr Peterborough ON K9L 0G2 Canada"},{"name":"SKiN Centre for Dermatology  775 Monaghan Road South Peterborough ON K9J 5K2 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Chandler","sequence":"additional","affiliation":[{"name":"Trent University  1600 West Bank Dr Peterborough ON K9L 0G2 Canada"},{"name":"SKiN Centre for Dermatology  775 Monaghan Road South Peterborough ON K9J 5K2 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novin","family":"Nezamololama","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology  775 Monaghan Road South Peterborough ON K9J 5K2 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research  139 Union St E Waterloo ON N2J 1C4 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Probity Medical Research  139 Union St E Waterloo ON N2J 1C4 Canada"},{"name":"Queen\u2019s University  99 University Ave Kingston ON K7L 3N6 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.032"},{"key":"e_1_2_7_3_1","first-page":"293","article-title":"Atopic dermatitis in children","volume":"45","author":"Page SS","year":"2016","journal-title":"Aust Fam Phys"},{"key":"e_1_2_7_4_1","first-page":"1078","article-title":"The impact of lifestyle factors on evolution of atopic dermatitis: an alternative approach (review)","volume":"17","author":"Solomon I","year":"2019","journal-title":"Exp Ther Med"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/23312025.2015.1103459"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-0032-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.030"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2006.01047.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02342"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1828068"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212595"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00588\u20102"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","unstructured":"ReichK TeixeiraHD deBruin\u2010WellerM et\u2009al.Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate\u2010To\u2010Severe Atopic Dermatitis: Results From the Pivotal Phase 3 Randomized Double\u2010Blinded Placebo\u2010Controlled AD Up Study.Presented at the 3rd Revolutionizing Atopic Dermatitis Virtual Conference. 2020. (NCT03568318).","DOI":"10.2139\/ssrn.3748383"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30032-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.018"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14871"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01186"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.4.supp.95"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01291-2"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16014"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.004"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40798"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41580"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.001"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1866-2"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15853","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T14:04:41Z","timestamp":1692885881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/ijd.15853"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15853","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,22]]},"assertion":[{"value":"2021-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}